目的 研究天津市人民醫(yī)院口服降糖藥的使用情況，為臨床合理應用提供參考。方法 對2014-2016年天津市人民醫(yī)院口服降糖藥的用量、銷售金額、用藥頻度（DDDs）、日均藥費（DDC）等進行統(tǒng)計和分析。結(jié)果 2014-2016年，口服降糖藥的品種、總銷售金額及總DDDs均保持穩(wěn)定；α-糖苷酶抑制劑、磺酰脲類促胰島素分泌劑、雙胍類DDDs占主導地位，構成比占80%以上；促胰島素分泌劑和DPP-4抑制劑的DDDs呈逐年增長趨勢。阿卡波糖、二甲雙胍、伏格列波糖的DDDs排名穩(wěn)居前3位；格列喹酮、那格列奈、沙格列汀、阿格列汀的DDDs增長速度較快。2016年因價格政策影響，口服降糖藥的DDC略有下降，阿卡波糖的DDC最高，格列齊特最低。阿卡波糖、格列美脲、吡格列酮、那格列奈、格列吡嗪、格列齊特、沙格列汀、阿格列汀的B/A值接近或等于1。結(jié)論 天津市人民醫(yī)院口服降糖藥的使用基本合理，α-糖苷酶抑制劑、磺酰脲類促胰島素分泌劑、雙胍類為臨床首選藥品。

Objective To evaluate the usage of oral antidiabetic drugs in Tianjin Union Medicine Centre, in order to provide a reference for clinical rational drug use. Methods Amounts, consumption sum, defined daily doses (DDDs), and defined daily cost (DDC), etc. in Tianjin Union Medicine Centre fom 2014 to 2016 were analyzed statistically. Results Consumption sum and DDDs were stable in general for three years. Glycosidase inhibitors, sulfonylureas, and biguanides accounted for 80% of DDDs. DDDs of insulin secretagogues and DPP-4 inhibitors were increased year by year. Acarbose, metformin, and voglibose kept top three in respect of DDDs. Gliquidone, nateglinide, saxagliptin, and alogliptin showed a rapid upward trend as single-drug. DDC of oral antidiabetic drugs dropped influenced by price policy in 2016. DDC of acarbose was the highest, and gliclazide was the lowest. B/A of acarbose, glimepiride, pioglitazone, nateglinide, glipizide, saxagliptin, and alogliptin were next to 1. Conclusion The application of oral antidiabetic drugs in Tianjin Union Medicine Centre is basically rational. Glycosidase inhibitors, sulfonylureas, and biguanides are preferred in clinic.